Combining curcumin (diferuloylmethane) and heat shock protein inhibition for neurofibromatosis 2 treatment: Analysis of response and resistance pathways

Molecular Cancer Therapeutics

Volumn 10, Issue 11, 2011, Pages 2094-2103

  Angelo, Laura S ^a   Wu, Ji Yuan ^a   Meng, Feng ^a   Sun, Michael ^a   Kopetz, Scott ^a   McCutcheon, Ian E ^a   Slopis, John M ^a   Kurzrock, Razelle ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CURCUMIN; HEAT SHOCK PROTEIN 70; KNK 437; MERLIN; MITOGEN ACTIVATED PROTEIN KINASE 1; PROTEIN INHIBITOR; PROTEIN KINASE B; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CELL PROLIFERATION; CELL SURVIVAL; DOWN REGULATION; HUMAN; HUMAN CELL; IN VITRO STUDY; NEUROFIBROMATOSIS; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN DEPHOSPHORYLATION; PROTEIN PHOSPHORYLATION; UPREGULATION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BENZHYDRYL COMPOUNDS; CELL LINE, TUMOR; CELL PROLIFERATION; CURCUMIN; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; GENE EXPRESSION REGULATION, NEOPLASTIC; HEAT-SHOCK PROTEINS; HSP72 HEAT-SHOCK PROTEINS; HUMANS; MYOSIN-LIGHT-CHAIN PHOSPHATASE; NEUROFIBROMATOSIS 2; NEUROFIBROMIN 2; PHOSPHORYLATION; PROTEIN BINDING; PYRROLIDINONES; SIGNAL TRANSDUCTION; UP-REGULATION;

EID: 81055124264     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-11-0243     Document Type: Article

References (50)

1. Evans DG, Howard E, Giblin C, Clancy T, Spencer H, Huson SM, et al. Birth incidence and prevalence of tumor-prone syndromes: estimates from a UK family genetic register service. Am J Med Genet A 2010;152A:327-32.
2. Asthagiri AR, Parry DM, Butman JA, Kim HJ, Tsilou ET, Zhuang Z, et al. Neurofibromatosis type 2. Lancet 2009;373:1974-86.
3. Plotkin SR, Stemmer-Rachamimov AO, Barker FG, Halpin C, Padera TP, Tyrrell A, et al. Hearing improvement after bevacizumab in patients with neurofibromatosis type 2. N Engl J Med 2009;361:358-67.
4. Evans DG, Kalamarides M, Hunter-Schaedle K, Blakeley J, Allen J, Babovic-Vuskanovic D, et al. Consensus recommendations to accelerate clinical trials for neurofibromatosis type 2. Clin Cancer Res 2009;15:5032-9.
5. Mohyuddin A, Neary WJ, Wallace A, Wu CL, Purcell S, Reid H, et al. Molecular genetic analysis of the NF2 gene in young patients with unilateral vestibular schwannomas. J Med Genet 2002;39:315-22. (Pubitemid 34526350)
6. Evans DGR, Ramsden RT, Shenton A, Gokhale C, Bowers NL, Huson SM, et al. Mosaicism in neurofibromatosis type 2: an update of risk based on uni/bilaterality of vestibular schwannoma at presentation and sensitive mutation analysis including multiple ligation-dependent probe amplification. J Med Genet 2007;44:424-28. (Pubitemid 47056867)
7. Okada T, You L, Giancotti FG. Shedding light on merlin's wizardry. Trends Cell Biol 2007;17:222-9. (Pubitemid 46679247)
8. Kissil JL, Wilker EW, Johnson KC, Eckman MS, Yaffe MB, Jacks T. Merlin, the product of the NF2 tumor suppressor gene, is an inhibitor of the p21-activated kinase, Pak1. Mol Cell 2003;12:841-9. (Pubitemid 37352778)
9. Xiao GH, Beeser A, Chernoff J, Testa JR. p21-activated kinase links Rac/Cdc42 signaling to merlin. J Biol Chem 2002;277:883-6. (Pubitemid 34968830)
10. Thaxton C, Lopera J, Bott M, Fernandez-Valle C. Neuregulin and laminin stimulate phosphorylation of the NF2 tumor suppressor in Schwann cells by distinct protein kinase A and p21-activated kinase-dependent pathways. Oncogene 2008;27:2705-15. (Pubitemid 351581460)
11. Tang X, Jang S-W, Wang X, Liu Z, Bahr SM, Sun SY, et al. Akt phosphorylation regulates the tumour-suppressor merlin through ubiquitination and degradation. Nat Cell Biol 2007;9:1199-1207. (Pubitemid 47500497)
12. Rong R, Tang X, Gutmann DH, Ye K. Neurofibromatosis 2 (NF2) tumor suppressor merlin inhibits phosphatidylinositol 3-kinase through binding to PIKE-L. Proc Natl Acad Sci U S A 2004;101:18200-5. (Pubitemid 40054097)
13. Hatchera H, Planalp R, Chob J, Torti FM, Torti SV. Curcumin: from ancient medicine to current clinical trials. Cell Mol Life Sci 2008;65:1631-52.
14. Rashmi R, Kumar S, Karunagaran D. Ectopic expression of Hsp70 confers resistance and silencing its expression sensitizes human colon cancer cells to curcumin-induced apoptosis. Carcinogenesis 2004;25:179-87. (Pubitemid 38239801)
15. Khar A, Ali AM, Pardhasaradhi BV, Varalakshmi CH, Anjum R, Kumari AL. Induction of stress response renders human tumor cell lines resistant to curcumin-mediated apoptosis: role of reactive oxygen intermediates. Cell Stress Chaperones 2001;6:368-76. (Pubitemid 33123490)
16. Kato K, Ito H, Kamei K, Iwamoto I. Stimulation of the stress-induced expression of stress proteins by curcumin in cultured cells and in rat tissues in vivo. Cell Stress Chaperones 1998;3:152-60. (Pubitemid 28434679)
17. Hung G, Faudoa R, Li X, Xeu Z, Brackmann DE, Hitselberg W, et al. Establishment of primary vestibular schwannoma cultures from neurofibromatosis type-2 patients. Int J Oncol 1999;14:409-15.
18. Hung G, Li X, Faudoa R, Xeu Z, Kluwe L, Rhim JS, et al. Establishment and characterization of a schwannoma cell line from a patient with neurofibromatosis 2. Int J Oncol 2002;20:475-82.
19. Chang LS, Akhmametyeva EM, Wu Y, Zhu L, Welling DB. Multiple transcription initiation sites, alternative splicing, and differential polyadenylation contribute to the complexity of human neurofibromatosis 2 transcripts. Genomics 2002;79:63-76. (Pubitemid 34112068)
20. Li L, Braiteh F, Kurzrock R. Liposome-encapsulated curcumin: in vitro and in vivo effects on proliferation, apoptosis, signaling, and angiogenesis. Cancer 2005;104:1322-31. (Pubitemid 41282806)
21. Hansen MB, Nielsen SE, Berg K. Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill. J Immunol Methods 1989;119:203-10. (Pubitemid 19132276)
22. Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 2006;58:621-81.
23. Chou TC. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res 2010;70:440-6.
24. Wang H, Joseph JA. Quantifying cellular oxidative stress by dichlorofluorescein assay using microplate reader. Free Radic Biol Med 1999;27:612-6. (Pubitemid 29408648)
25. Li L, Aggarwal BB, Shishodia S, Abbruzzese J, Kurzrock R. Nuclear factor-kappa-B and IkappaB kinase are constitutively active in human pancreatic cells, and their down-regulation by curcumin (diferuloylmethane) is associated with the suppression of proliferation and the induction of apoptosis. Cancer 2004;101:2351-62. (Pubitemid 39458693)
26. Li L, Ahmed B, Mehta K, Kurzrock R. Liposomal curcumin with and without oxaliplatin: effects on cell growth, apoptosis, and angiogenesis in colorectal cancer. Mol Cancer Ther 2007;6:1276-82. (Pubitemid 46711990)
27. 2/M arrest and apoptosis in cisplatin-resistant human ovarian cancer cells by modulating Akt and p38 MAPK. Cancer Biol Ther 2007;6:178-84.
28. Shankar S, Srivastava RK. Involvement of Bcl-2 family members, phosphatidylinositol 3′-kinase/AKT and mitochondrial p53 in curcumin (diferulolylmethane)-induced apoptosis in prostate cancer. Int J Oncol 2007;30:905-18.
29. Reuter S, Eifes S, Dicato M, Aggarwal BB, Diederich M. Modulation of anti-apoptotic and survival pathways by curcumin as a strategy to induce apoptosis in cancer cells. Biochem Pharm 2008;76:1340-51.
30. Siwak DR, Shishodia S, Aggarwal BB, Kurzrock R. Curcumin-induced anti-proliferative and pro-apoptotic effects in melanoma cells are associated with suppression of Ikappa B kinase and nuclear factor kappa B activity and are independent of the b-raf/mitogen-activated/extracellular signal-regulated protein kinase pathway and the Akt pathway. Cancer 2005;104:879-90. (Pubitemid 41113691)
31. Aggarwal S, Ichikawa H, Takada Y, Sandur SK, Shishodia S, Aggarwal BB. Curcumin (Diferuloylmethane) down-regulates expression of cell proliferation and anti-apoptotic and metastatic gene products through suppression of IkappaB kinase and Akt activation. Mol Pharmacol 2006;69:195-206. (Pubitemid 43048906)
32. Manning BD, Cantley LC. AKT/PKB signaling: navigating downstream. Cell 2007;129:1261-74. (Pubitemid 46962095)
33. Sainio M, Jaaskelainen J, Pihlaja H, Carpen O. Mild familial neurofibromatosis 2 associates with expression of merlin with altered COOH-terminus. Neurology 2000;54:1132-8. (Pubitemid 30151858)
34. Lepont P, Stickney JT, Foster LA, Meng JJ, Hennigan RF, Ip W. Point mutation in the NF2 gene of HEI-193 human schwannoma cells results in the expression of a merlin isoform with attenuated growth suppressive activity. Mutation Res 2008;637:142-51. (Pubitemid 350256772)
35. Pykett MJ, Murphy M, Harnish PR, George DL. The neurofibromatosis 2 (NF2) tumor suppressor gene encodes multiple alternatively spliced transcripts. Hum Mol Genet 1994;3:559-64. (Pubitemid 24122166)
36. Ito M, Nakano T, Erdodi F, Hartshorne DJ. Myosin phosphatase: Structure, regulation and function. Mol Cell Biochem 2004;259:197-209. (Pubitemid 38519232)
37. Scoles DR. The merlin interacting proteins reveal multiple targets for NF2 therapy. Biochim Biophys Acta 2008;1785:32-54.
38. Nonn L, Duong D, Peehl DM. Chemopreventive anti-inflammatory activities of curcumin and other phytochemicals mediated by MAP kinase phosphatase-5 in prostate cells. Carcinogenesis 2007;28:1188-96. (Pubitemid 47062677)
39. Huang J, Chen J. VprBP targets Merlin to the Roc1-Cul4A-DDB1 E3 ligase complex for degradation. Oncogene 2008;27:4056-64. (Pubitemid 351931990)
40. Ortiz-Ortiz MA, Moran JA, Bravosanpedro JM, González-Polo RA, Niso-Santano M, Anantharam V, et al. Curcumin enhances paraquat-induced apoptosis of N27 mesencephalic cells via the generation of reactive oxygen species. Neurotoxicology 2009;30:1008-18.
41. Thayyullathil F, Chathoth S, Hago A, Patel M, Galadari S. Rapid reactive oxygen species (ROS) generation induced by curcumin leads to caspase-dependent and -independent apoptosis in L929 cells. Free Radic Biol Med 2008;45:1403-12.
42. Teiten MH, Reuter S, Schmucker S, Dicato M, Diederich M. Induction of heat shock response by curcumin in human leukemia cells. Cancer Lett 2009;279:145-54.
43. Yokota S, Kitahara M, Nagata K. Benzylidene lactam compound, KNK437, a novel inhibitor of acquisition of thermotolerance and heat shock protein induction in human colon carcinoma cells. Cancer Res 2000;60:2942-8. (Pubitemid 30395819)
44. Koike T, Uno S, Ishizawa M, Takahashi H, Ikeda K, Yokota S, et al. The heat shock protein inhibitor KNK437 induces neurite outgrowth in PC12 cells. Neurosci Lett 2006;410:212-7. (Pubitemid 44750348)
45. Fraenzer JT, Pan H, Minimo L Jr, Smith GM, Knauer D, Hung G. Overexpression of the NF2 gene inhibits schwannoma cell proliferation through promoting PDGFR degradation. Int J Oncol 2003;23:1493-1500.
46. Daugaard M, Rohde M, Jaattela M. The heat shock protein 70 family: highly homologous proteins with overlapping and distinct functions. FEBS Lett 2007;581:3702-10. (Pubitemid 47081009)
47. Dhillon N, Aggarwal BB, Newman RA, Wolff RA, Kunnumakkara AB, Abbruzzese JL, et al. Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res 2008;14:4491-9.
48. Mach CM, Mathew L, Mosley SA, Kurzrock R, Smith JA. Determination of minimum effective dose and optimal dosing schedule for liposomal curcumin in a xenograft human pancreatic cancer model. Anticancer Res 2009;29:1895-1900.
49. Chin SF, Iyer KS, Saunders M, St Pierre TG, Buckley C, Paskevicius M, et al. Encapsulation and sustained release of curcumin using superparamagnetic silica reservoirs. Chemistry 2009;15:5661-5.
50. Sou K, Oyajobi B, Goins B, Phillips WT, Tsuchida E. Characterization and cytotoxicity of self-organized assemblies of curcumin and amphiphatic poly(ethylene glycol). J Biomed Nanotechnol 2009;5:202-8.